Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (608)	5/16/2006 5:36:41 AM
From: nigel bates	of 625

>>it's not the drug program....it has to be the shrinking antibody platform space as you all have suggested<< I'm not sure that it isn't both. John Patterson, executive director of drug development at AZ, said that the company had decided to (buy) CAT after the joint venture had exceeded all expectations. Mr Patterson added that he expected the first compound to go forward into development by the end of the year, well ahead of initial forecasts... Suggests to me that MAB generation is getting easier and more predictable for the big players. Add in that BF is getting serious about biologicals (cf Merck/Glycofi - not much of a pipeline there, but a serious program ...December of 2005, GlycoFi and Merck initiated a large, multi-year, multi-product research and development collaboration. Merck will integrate the GlycoFi technology into its biologic drug discovery process to optimize the therapeutic properties and potential of multiple classes of drug candidates, focusing on monoclonal antibodies and vaccines...)... that BF is getting overtaken by Amgen in market cap. and aquisition nous... that large, early stage and thinly funded MAB pipelines in small biotechs are potentially worth a lot more with full BF resources behind them... and it makes much more sense. GSK strategists (for example) are going to be putting in some late nights, IMO. (edit) And there was always the outside chance of a pre-emptive bid from GENZ to worry about... (edit 2) Also if GENZ or Amgen etc decide to use their paper for aquistions, BF will find it hard to compete without some dilution.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next